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While hepatic hemangiomas are the most common hepatic
tumors in children, giant hepatic hemangiomas with clinical
symptoms in neonates are rare.1 Accompanying complica-
tions, such as KasabacheMerritt syndrome and cardiac
failure, result in a high mortality rate in affected neo-
nates.2 There is no consensus on the treatment for critical
hepatic hemangiomas. Besides medical treatment, local
treatment such as endovascular intervention is an
alternative.* Corresponding author. Department of Pediatrics, National
Taiwan University Hospital, Department of Medical Education and
Bioethics, National Taiwan University College of Medicine, 17F,
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The patient was a male neonate born at 39 weeks of
gestation. His birth body weight was 3460 g. At 11 days of
age, the patient presented with fever, tachycardia
(160e170 beats/min), and tachypnea (60e70/min). Phys-
ical examination revealed distended abdomen and hepa-
tomegaly. A bruit was heard during auscultation at the right
upper quadrant of the abdomen. No cutaneous hemangio-
ma was found. Laboratory tests revealed leukocytosis
(white blood cells: 15,000/mL), thrombocytopenia (plate-
lets: 117,000/mL), and a normal hemoglobin level (hemo-
globin: 16.3 g/dL). The patient was then admitted.
Abdominal sonography revealed one heterogeneous
tumor, measuring 7.1 cm 5.9 cm in size, located at the S4,
S5, S6, and S8 regions of the liver (Figure 1A). The alpha-
fetoprotein level was 21,951 ng/mL, which was within the
normal range for neonates of this age. The tumor had high
signal intensity, with the observation of prominent flow
voids on the T2-weighted image after magnetic resonance
imaging (Figure 1B). A hemangioma was suspected.arterial Embolization and Propranolol as Effective Treatment for
ailure in a Neonate, Pediatrics and Neonatology (2016), http://
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coagulopathy (PT (Prothrombin time)/aPTT (Activated par-
tial thromboplastin time): 14.1/43.0 seconds; FDP (Fibrin
degradation product): 27.2 mg/mL; d-dimer: 9.34 mg/mL;
and fibrinogen: 271.5 mg/dL), a diagnosis of Kasa-
bacheMerritt syndrome was considered.
Medical treatment with propranolol was administered
initially. However, the patient subsequently developed
high-output heart failure that presented as tachycardia
(170e180 beats/min), preserved cardiac contractility, and
hyperdynamic heart in echocardiography. Middle cerebral
artery Doppler also revealed an elevated pulsatility index.
The pulsatility index was 2.54 on the right middle cerebral
artery and 2.32 on the left middle cerebral artery, which is
<2.0 in healthy newborns. It was believed to be secondary
to the arteriovenous shunting inside the tumor. Owing to
the risk of bleeding, surgical excision was not applicable.
Therefore, the radiologist performed transarterial emboli-
zation (TAE) when the infant was 21 days old. Angiography
revealed a hypervascular tumor supplied by both the
right and left hepatic arteries (Figure 1C). Embolization
was performed at the proper hepatic artery under
digital subtraction angiography by injecting microspheres
(100e300 mm) consisting of a hydrogel core and an outer
layer of a biocompatible polymer. The TAE took 15 minutes
and was performed smoothly, with only a small residualFigure 1 (A) Abdominal sonography revealed one heterogeneous
right and left hepatic veins (S4, S5, S6, and S8). (B) An intrahepati
weighted image of magnetic resonance imaging. (C) Angiography
right hepatic and left hepatic arteries. (D) Nine months after trea
decreased to 1.9 cm  2.4 cm.
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bruit disappeared after TAE. The infant’s respiratory rate
was 40e50/min and the heart rate was 130e140 beats/min,
which were within the normal range. Abdominal sonography
performed on the 7th day after TAE demonstrated a
decrease in the size of the tumor (5.7 cm  3.8 cm). The
platelet count recovered to the normal range (313,000/mL)
since the 7th day after TAE. Propranolol (1.5 mg/kg/d) was
continued, and the patient was discharged.
During the outpatient follow up, the size of the hem-
angioma in sonography decreased to 1.9 cm  2.4 cm at the
age of 9 months (Figure 1D). Propranolol was maintained
until the patient was 1 year old and then discontinued when
satisfactory improvement was noted. The patient had
normal growth and development when followed up to 1
year and 5 months of age.3. Discussion
For neonates with a large hemangioma, heart failure
caused by arteriovenous shunting and consumptive coa-
gulopathy can cause mortality if left untreated. In our case,
high-output heart failure and thrombocytopenia were
evident at the time of diagnosis. As surgical excision was
risky and medical treatment could be time consuming, TAEtumor, measuring 7.1 cm  5.9 cm in size, located between the
c mass lesion with heterogeneously high signal intensity on T2-
prior to embolization: a hypervascular tumor supplied by both
tment, the size of the hemangioma in abdominal sonography
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size of the vessels and the small amount of contrast me-
dium that neonates can tolerate are the two major con-
cerns of TAE in neonates. In the past decade, digital
subtraction angiography has made the injection of a lesser
amount of contrast medium possible for neonates. Another
concern of TAE is the unexpected hepatic damage due to
vascular compromise of the normal liver. Therefore, TAE is
indicated only if embolization can be performed at one or
few feeding arteries that only supply the hemangioma, as
observed in our case. Our experience demonstrated that
TAE can be applied to young infants with giant hepatic
hemangiomas as an alternative to surgery by an experi-
enced staff. The TAE could be curative. However, even if
the tumor did not regress completely, the immediate
improvement in clinical conditions, particularly heart fail-
ure and thrombocytopenia, remained a strong argument for
TAE. Warmann et al3 reported about four infants with
symptomatic hepatic hemangioendothelioma undergoing
coil embolization. Complete regression of the tumor was
achieved in three of the four patients within 54 months.
Our patient had partial regression of the tumor after 9
months. However, complications of TAE, such as liver fail-
ure, bile duct injury, hepatic abscess, and other unex-
pected thrombosis of the vessels, are still worth noticing.4
Serial follow up of liver function and close observation after
the procedure are important.
In addition to invasive intervention, medical treatment
for solid-organ infantile hemangiomas traditionally con-
sisted of corticosteroids, followed by interferon-a or other
cytotoxic agents. The potential side effects for infants
were of great concern. The use of propranolol for hepatic
hemangiomas has been reported with promising results in
recent years.5 The response rate exceeds that of systemic
corticosteroids and is much better tolerated.5e7 Our pa-
tient was administered oral propranolol at a dosage ofPlease cite this article in press as: Shen W-C, et al., Combined Trans
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up, the tumor size kept decreasing without noticeable side
effects. The use of propranolol may play a role in the
regression of the tumor.
In summary, we present a case of intrahepatic heman-
gioma with high-output cardiac failure and Kasa-
bacheMerritt syndrome in a neonate. The successful
treatment with TAE combined with propranolol therapy is
encouraging and deserves further evaluation.Conflicts of interest
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